

Catalent and CTC to take Korean pharma to US, EU

17 September 2012 | News | By BioSpectrum Bureau



Singapore: Catalent Pharma Solutions and CTC Bio entered into a collaboration to provide optimal solutions to South Korean pharmaceutical companies seeking to commercialize solid oral dose and controlled release products in the US and Europe.

Combining CTC Bio's leading position in the region with Catalent's expertise in controlled release formulations, manufacturing network and broad experience in global product launches will provide South Korean companies with unparalleled access to international markets.

Dr HR Jeon, CSO, CTC Bio, said that, "South Korea is a highly innovative region, developing new products and effective pharmaceutical formulations. This collaboration with Catalent provides South Korean pharmaceutical customers with better access to the leading provider of innovative controlled release drug delivery technologies and supply capabilities."

Mr Ian Muir, president, modified release technologies business, Catalent, commented that, "CTC Bio is a leading regional provider of innovative drug products and formulation services and its capabilities perfectly complement those of Catalent. In collaboration with CTC Bio, Catalent can now provide South Korean pharmaceutical customers with seamless scale-up and transfer within Catalent's controlled release capabilities at our Winchester, KY and Somerset, NJ facilities in the US and at Schorndorf, Germany in Europe.

"These are leading commercial facilities for oral solids and controlled release dosage forms, ensuring that commercial manufacture for global supply is carried within the target markets and meets all international standards of quality and reliability," he added.